MediFind Becomes First Doctor Directory to Receive the Digital Medicine Society Seal

Key Terms

digital health medical

Digital health involves the use of technology, such as apps, wearable devices, and online platforms, to monitor, manage, and improve people's health and healthcare. For investors, it represents a growing industry that combines healthcare with digital innovation, offering new ways to deliver medical services and track wellness, which can lead to advancements in patient care and potential business opportunities.

clinical evidence medical

Results and observations gathered from studies in people that show whether a medical treatment, device, or diagnostic works and is safe; think of it as the real-world road test that moves an idea from the lab into practical use. Investors watch clinical evidence because strong, reliable results reduce regulatory and commercial risk, increase the chances of approval and reimbursement, and help predict future sales — similar to how a positive product review can boost consumer demand.

privacy and security technical

Privacy and security are the policies, technologies and everyday practices a company uses to keep customer, employee and business information safe from unauthorized access, theft or misuse. Investors watch these safeguards because data breaches and weak protections can lead to direct financial losses, regulatory fines and lasting reputational harm — like a business losing the keys to its safe — which can lower revenue, raise costs and hurt a company’s stock value.

rare disease medical

A rare disease is a medical condition that affects a very small portion of the population, often so uncommon that doctors see it rarely — like a problem that needs a specialized tool. It matters to investors because treatments for these conditions can command higher prices, face fewer competing products, and often receive special government incentives and faster review, but they also carry higher scientific and commercial risk due to small patient numbers.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ALL-REMOTE COMPANY/WILMINGTON, Del.--(BUSINESS WIRE)-- MediFind, a leading data-powered online provider directory, is proud to announce it received the DiMe Seal, developed by the Digital Medicine Society (DiMe), an independent nonprofit advancing the safe and effective use of digital health. MediFind is the first doctor directory to be awarded this seal.

DiMe evaluates platforms based on core principles such as clinical evidence, privacy and security, and usability. The DiMe seal helps individuals make informed choices and identify which digital health tools meet a higher standard of trust.

Finding the right doctor—whether for a rare disease or a more common condition—can feel overwhelming. With so many options online, consumers struggle with knowing where to begin. As a result, many look for resources they can trust when they are making decisions about healthcare. MediFind uses advanced analytics to help consumers with data-driven, evidence-based information, making the provider search process more efficient and impactful.

“We’re honored to receive the DiMe Seal as a testament to the trustworthiness of MediFind,” said David Linetsky, President of Phreesia Network Solutions. “This is a meaningful milestone in our commitment to make it easier for people to find care.”

Although many people turn to digital tools as a first step when looking for care, reliable health information isn’t always easy to find online. Many people have difficulty evaluating which sources to trust, and because the accuracy and transparency of online health information can vary widely, it is challenging for consumers to determine which sources are trustworthy.

Frameworks like the DiMe Seal help make that process easier by highlighting platforms that meet higher standards for transparency and reliability. The credibility of a doctor directory is particularly important for those with serious, chronic and rare diseases who may not know where to start when it comes to finding the right specialist for their condition. Specialists who are familiar with the latest research and developments related to a patient’s rare disease can help get that patient on a treatment plan that would give them their best chance for successful outcomes.

Phreesia acquired MediFind in July 2023. To learn more about MediFind, visit MediFind.com.

About Phreesia

Phreesia is the trusted leader in patient activation, giving healthcare providers, life sciences companies and other organizations tools to help patients take a more active role in their care. Founded in 2005, Phreesia enabled more than 180 million patient visits in 2025—1 in 6 visits across the U.S. This scale allows Phreesia to make meaningful impact across the healthcare ecosystem. Offering patient-driven digital solutions for intake, outreach, education and more, Phreesia enhances the patient experience, drives operational efficiency and improves healthcare outcomes. To learn more, visit phreesia.com.

About MediFind

MediFind is a data science and consumer-centric health technology company, focusing on connecting patients with leading experts, clinical trials, health systems, and healthcare technologies through advanced analytics. The company employs machine learning techniques and artificial intelligence technologies to synthesize the latest information from around the globe on a range of chronic and rare conditions with the goal of helping patients make more informed health decisions faster. Learn more about MediFind at www.medifind.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260409055049/en/

media@phreesia.com

Source: Phreesia, Inc.